scholarly article | Q13442814 |
P50 | author | Kelly M. McMasters | Q55615790 |
Pei-Hsin Cheng | Q87689932 | ||
P2093 | author name string | H Sam Zhou | |
Jorge G Gomez-Gutierrez | |||
Xiao-Mei Rao | |||
Stephen L Wechman | |||
P2860 | cites work | Functions of the adenovirus E1B tumour antigens. | Q53540498 |
[Phase II clinical study of intratumoral H101, an E1B deleted adenovirus, in combination with chemotherapy in patients with cancer] | Q64377248 | ||
Gene expression profiles of normal human lung cells affected by adenoviral E1B | Q64377980 | ||
Phase II clinical trial of intralesional administration of the oncolytic adenovirus ONYX-015 in patients with hepatobiliary tumors with correlative p53 studies | Q64378032 | ||
E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells | Q64379383 | ||
A combined assay of cell viability and in vitro cytotoxicity with a highly water-soluble tetrazolium salt, neutral red and crystal violet | Q71850183 | ||
Reduced expression of microtubule-associated protein 1 light chain 3 in hypertrophic scars | Q83214323 | ||
Oncolytic virotherapy | Q38025263 | ||
Too much or not enough of a good thing--The Janus faces of autophagy in cardiac fuel and protein homeostasis | Q38377805 | ||
Isolation of more potent oncolytic paramyxovirus by bioselection | Q39392034 | ||
Verapamil enhances the antitumoral efficacy of oncolytic adenoviruses | Q39735941 | ||
Bak and Bax function to limit adenovirus replication through apoptosis induction | Q39752946 | ||
Bioselection of a gain of function mutation that enhances adenovirus 5 release and improves its antitumoral potency. | Q39923110 | ||
Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. | Q40018751 | ||
Conditionally replicating adenoviruses kill tumor cells via a basic apoptotic machinery-independent mechanism that resembles necrosis-like programmed cell death | Q40277603 | ||
Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. | Q40341364 | ||
Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. | Q41563742 | ||
Stabilization of the p53 tumor suppressor is induced by adenovirus 5 E1A and accompanies apoptosis | Q41563751 | ||
Isolation of adenovirus type 5 host range deletion mutants defective for transformation of rat embryo cells | Q41975913 | ||
Advantages and disadvantages of multiple different methods of adenoviral vector construction | Q44267578 | ||
A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models | Q44984285 | ||
A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy | Q45247385 | ||
Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. | Q45862986 | ||
Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial | Q45876506 | ||
Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas | Q45880512 | ||
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing | Q24597817 | ||
Oncolytic Replication of E1b-Deleted Adenoviruses | Q26777406 | ||
Molecular dissection of autophagy: two ubiquitin-like systems | Q28206420 | ||
Molecular basis for viral selective replication in cancer cells: activation of CDK2 by adenovirus-induced cyclin E | Q28486255 | ||
Development by self-digestion: molecular mechanisms and biological functions of autophagy | Q29547880 | ||
Current issues and future directions of oncolytic adenoviruses | Q33730705 | ||
A phase I study of telomerase-specific replication competent oncolytic adenovirus (telomelysin) for various solid tumors | Q33730735 | ||
To cycle or not to cycle: a critical decision in cancer. | Q33957955 | ||
Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? | Q34225918 | ||
Autophagy: assays and artifacts | Q34341096 | ||
An adenovirus mutant that replicates selectively in p53-deficient human tumor cells | Q34399844 | ||
Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials | Q34452020 | ||
Developing novel oncolytic adenoviruses through bioselection | Q34471952 | ||
Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection | Q34562704 | ||
Adenovirus and cell cycle control | Q34625673 | ||
Adenoviruses induce autophagy to promote virus replication and oncolysis. | Q35040642 | ||
Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter | Q35058583 | ||
Phase I clinical trial of locoregional administration of the oncolytic adenovirus ONYX-015 in combination with mitomycin-C, doxorubicin, and cisplatin chemotherapy in patients with advanced sarcomas | Q35234338 | ||
Cancer-specific viruses and the development of ONYX-015 | Q35542812 | ||
Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice | Q35811062 | ||
Intra-tumor injection of H101, a recombinant adenovirus, in combination with chemotherapy in patients with advanced cancers: a pilot phase II clinical trial | Q36180392 | ||
Recent progress in the battle between oncolytic viruses and tumours | Q36315580 | ||
Clinical trials with oncolytic adenovirus in China | Q36754441 | ||
Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer | Q36803773 | ||
The 19-Kilodalton Adenovirus E1B Transforming Protein Inhibits Programmed Cell Death and Prevents Cytolysis by Tumor Necrosis Factor α | Q36816831 | ||
Cellular genetic tools to control oncolytic adenoviruses for virotherapy of cancer | Q37063332 | ||
The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins | Q37162513 | ||
Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells | Q37362758 | ||
Oncolytic viral therapy of malignant glioma | Q37533665 | ||
Strategies to enhance viral penetration of solid tumors | Q37858538 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | Adenoviridae | Q193447 |
oncolytic virus | Q1560099 | ||
P577 | publication date | 2016-06-14 | |
P1433 | published in | Viruses | Q7935305 |
P1476 | title | Development of an Oncolytic Adenovirus with Enhanced Spread Ability through Repeated UV Irradiation and Cancer Selection | |
P478 | volume | 8 |
Q37539305 | Adenovirus with DNA Packaging Gene Mutations Increased Virus Release |
Q64374652 | Targeting Palbociclib-Resistant Estrogen Receptor-Positive Breast Cancer Cells via Oncolytic Virotherapy |
Q54207869 | Temozolomide Enhances Triple-Negative Breast Cancer Virotherapy In Vitro. |
Q47564266 | Temozolomide renders murine cancer cells susceptible to oncolytic adenovirus replication and oncolysis |
Q57171688 | The role of JNK phosphorylation as a molecular target to enhance adenovirus replication, oncolysis and cancer therapeutic efficacy |
Search more.